

**The Patient: Patient-Centered Outcomes Research**

**Electronic Supplementary Materials for:**

**Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase 3 Non-Inferiority Trials of Adults with HIV on Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Coformulated Abacavir, Dolutegravir, and Lamivudine**

David Wohl, MD<sup>1</sup>; Amanda Clarke, MD<sup>2</sup>; Franco Maggiolo, MD<sup>3</sup>; Will Garner, PhD<sup>4</sup>;  
Marianne Laouri, PhD<sup>4</sup>; Hal Martin, MD<sup>4</sup>; Erin Quirk, MD<sup>4</sup>

<sup>1</sup> University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; <sup>2</sup> Royal Sussex County Hospital, Brighton, UK; <sup>3</sup> ASST Papa Giovanni XXIII, Bergamo, IT; <sup>4</sup>Gilead Sciences, Inc., Foster City, CA, USA

**Corresponding Author:**

Will Garner, PhD

Gilead Sciences, Inc.

Email: will.garner@gilead.com

**Electronic Supplementary Materials Table 1a: Unadjusted and Adjusted Associations between Treatment and Bothersome Symptoms at Weeks 4, 12 and 48 in Study GS-US-380-1489 (Treatment-Naïve)**

Symptom Description OR (95% CI), p-value	Week 4		Week 12		Week 48	
	Unadjusted	Adjusted	Unadjusted	Adjusted	Unadjusted	Adjusted
<b>Fatigue/loss of energy</b>	0.68 (0.49-0.94), 0.018	0.58 (0.40-0.84), 0.004 <sup>a,f,g</sup>	0.70 (0.51-0.98), 0.036	0.62 (0.43-0.89), 0.010 <sup>a,f,g</sup>	0.69 (0.49-0.96), 0.030	0.57 (0.39-0.85), 0.005 <sup>a,b,f,g</sup>
Fevers/chills/sweats	1.12 (0.75-1.66), 0.58	1.03 (0.67-1.60), 0.89 <sup>a</sup>	0.89 (0.57-1.38), 0.59	0.81 (0.50-1.31), 0.39 <sup>a</sup>	1.05 (0.67-1.64), 0.84	1.10 (0.68-1.80), 0.69 <sup>a,e,f</sup>
<b>Dizzy/lightheadedness</b>	0.69 (0.47-1.02), 0.066	0.59 (0.39-0.91), 0.016 <sup>a</sup>	0.83 (0.54-1.27), 0.38	0.74 (0.46-1.17), 0.20 <sup>a,g</sup>	0.54 (0.35-0.84), 0.006	0.47 (0.29-0.77), 0.003 <sup>a,f,g</sup>
Pain/numbness/tingling in hands/feet	0.86 (0.56-1.32), 0.49	0.82 (0.50-1.32), 0.41 <sup>a,f</sup>	0.92 (0.60-1.41), 0.71	0.85 (0.53-1.35), 0.49 <sup>a,f</sup>	0.97 (0.64-1.46), 0.88	0.95 (0.60-1.50), 0.83 <sup>a,f</sup>
Trouble remembering	1.07 (0.72-1.59), 0.73	0.95 (0.60-1.50), 0.82 <sup>a,e,g</sup>	1.22 (0.83-1.78), 0.31	1.19 (0.77-1.84), 0.43 <sup>a,f,g</sup>	0.96 (0.65-1.43), 0.84	0.89 (0.57-1.40), 0.62 <sup>a,f</sup>
<b>Nausea/vomiting</b>	0.51 (0.34-0.77), 0.001	0.47 (0.30-0.73), <0.001 <sup>b</sup>	0.44 (0.26-0.74), 0.002	0.39 (0.23-0.68), <0.001 <sup>g</sup>	0.75 (0.44-1.26), 0.27	0.70 (0.40-1.23), 0.21 <sup>a,b,f</sup>
Diarrhea/loose bowels	0.97 (0.66-1.42), 0.87	0.90 (0.59-1.36), 0.60 <sup>a,e</sup>	0.80 (0.53-1.22), 0.30	0.78 (0.51-1.21), 0.27 <sup>a,f</sup>	0.76 (0.47-1.23), 0.26	0.69 (0.41-1.17), 0.17 <sup>a,e,f</sup>
Sad/down/depressed	0.85 (0.61-1.19), 0.35	0.69 (0.45-1.06), 0.086 <sup>a,g</sup>	1.04 (0.74-1.46), 0.82	0.96 (0.64-1.43), 0.83 <sup>a,e,g</sup>	0.84 (0.59-1.19), 0.33	0.72 (0.47-1.09), 0.12 <sup>a,e,g</sup>
Nervous/anxious	0.96 (0.68-1.34), 0.80	0.80 (0.52-1.22), 0.30 <sup>a,e,g</sup>	0.89 (0.63-1.27), 0.53	0.79 (0.53-1.18), 0.25 <sup>a,e,g</sup>	0.93 (0.66-1.33), 0.70	0.85 (0.56-1.28), 0.43 <sup>a,d,e,g</sup>
<b>Difficulty sleeping</b>	0.88 (0.63-1.22), 0.45	0.79 (0.54-1.17), 0.24 <sup>a,e,f</sup>	0.66 (0.47-0.93), 0.017	0.58 (0.40-0.85), 0.005 <sup>a,c,d,f</sup>	0.73 (0.52-1.03), 0.075	0.64 (0.44-0.94), 0.022 <sup>a,b,g</sup>
Skin problems/rash/itching	0.80 (0.55-1.16), 0.23	0.68 (0.45-1.03), 0.070 <sup>a</sup>	0.84 (0.57-1.25), 0.40	0.78 (0.51-1.18), 0.24 <sup>a,f</sup>	0.92 (0.62-1.37), 0.69	0.91 (0.60-1.38), 0.65 <sup>a,f</sup>
Coughing/trouble breathing	0.96 (0.60-1.51), 0.84	0.92 (0.55-1.53), 0.75 <sup>a,f</sup>	1.04 (0.66-1.64), 0.87	1.08 (0.66-1.77), 0.75 <sup>a,f</sup>	0.88 (0.55-1.42), 0.61	0.83 (0.49-1.41), 0.49 <sup>a,f,g</sup>
<b>Headaches</b>	0.89 (0.61-1.31), 0.55	0.86 (0.57-1.29), 0.47 <sup>a,d</sup>	0.86 (0.58-1.28), 0.45	0.80 (0.52-1.24), 0.32 <sup>a,b,c</sup>	0.50 (0.33-0.78), 0.002	0.46 (0.29-0.73), 0.001 <sup>a</sup>
<b>Loss of appetite</b>	0.78 (0.50-1.22), 0.27	0.67 (0.39-1.14), 0.14 <sup>a,b,f</sup>	0.53 (0.33-0.84), 0.007	0.43 (0.25-0.72), 0.002 <sup>a,b,f</sup>	0.72 (0.43-1.21), 0.22	0.61 (0.33-1.10), 0.10 <sup>a,b,f</sup>
<b>Bloating/pain/gas in stomach</b>	1.00 (0.69-1.44), 0.98	0.95 (0.63-1.42), 0.81 <sup>a,b,f</sup>	0.90 (0.61-1.33), 0.60	0.86 (0.57-1.30), 0.48 <sup>a</sup>	0.67 (0.45-1.00), 0.048	0.61 (0.40-0.93), 0.022 <sup>a,f</sup>
Muscle aches/joint pain	0.89 (0.60-1.31), 0.55	0.88 (0.56-1.39), 0.59 <sup>a,c,f</sup>	1.07 (0.74-1.57), 0.71	1.08 (0.71-1.64), 0.73 <sup>a,b,f,g</sup>	0.82 (0.56-1.20), 0.30	0.80 (0.52-1.24), 0.31 <sup>a,b,c,f</sup>
Problems with sex	1.10 (0.73-1.66), 0.65	1.03 (0.66-1.62), 0.88 <sup>a,f,g</sup>	1.13 (0.74-1.72), 0.57	1.04 (0.66-1.62), 0.88 <sup>a,g</sup>	0.91 (0.60-1.39), 0.66	0.86 (0.55-1.37), 0.53 <sup>a,f,g</sup>
Changes in body composition	1.23 (0.77-1.95), 0.38	1.22 (0.74-2.02), 0.44 <sup>a,d,f</sup>	1.18 (0.77-1.81), 0.46	1.14 (0.73-1.80), 0.56 <sup>a</sup>	0.82 (0.55-1.21), 0.32	0.73 (0.47-1.12), 0.15 <sup>a,f</sup>
<b>Weight loss/wasting</b>	1.02 (0.60-1.75), 0.93	0.92 (0.51-1.67), 0.79 <sup>a,b,f</sup>	0.61 (0.35-1.06), 0.079	0.53 (0.29-0.97), 0.039 <sup>a</sup>	1.02 (0.61-1.69), 0.94	0.95 (0.55-1.66), 0.87 <sup>a,f</sup>
Hair loss/changes	0.69 (0.38-1.24), 0.21	0.52 (0.27-1.01), 0.053 <sup>a,b,d</sup>	0.80 (0.44-1.46), 0.47	0.70 (0.37-1.34), 0.28 <sup>a,d</sup>	0.60 (0.32-1.15), 0.13	0.51 (0.25-1.04), 0.064 <sup>a,d</sup>

Adjusted logistic regression model includes treatment as the independent variable and the bothersome HIVSI item as the dependent variable, adjusted for Baseline HIVSI count, age, sex, Baseline VACS Index, serious mental illness, Baseline SF-36 PCS, and Baseline SF-36 MCS.

P-value is for treatment effect; bolding indicates significant treatment effect in one or more of the models.

The following covariates were statistically significant (p<0.05) in the model: <sup>a</sup>Baseline HIVSI count; <sup>b</sup>Age; <sup>c</sup>Sex; <sup>d</sup>Baseline VACS Index; <sup>e</sup>Serious mental illness; <sup>f</sup>Baseline SF-36 PCS; <sup>g</sup>Baseline SF-36 MCS.

An odds ratio (OR) < 1 represents less bothersome symptom for B/F/TAF

<b>Electronic Supplementary Materials Table 1a-2: Bayesian information criterion (BIC) for Unadjusted and Adjusted Associations between Treatment and Bothersome Symptoms at Weeks 4, 12 and 48 in Study GS-US-380-1489 (Treatment-Naïve)</b>									
<b>Symptom Description, BIC</b>	<b>Week 4</b>			<b>Week 12</b>			<b>Week 48</b>		
	<b>Unadjusted</b>	<b>Adjusted</b>	<b>Diff</b>	<b>Unadjusted</b>	<b>Adjusted</b>	<b>Diff</b>	<b>Unadjusted</b>	<b>Adjusted</b>	<b>Diff</b>
Fatigue/loss of energy	856.3	748.6	107.7	824.5	739.4	85.1	786.3	677.2	109.1
Fevers/chills/sweats	628.8	577.4	51.4	528.5	506.9	21.6	513.6	486.1	27.5
Dizzy/lightheadedness	642.3	617.1	25.2	557.8	538.3	19.5	548.4	509.1	39.3
Pain/numbness/tingling in hands/feet	554.3	505	49.3	570.9	533.2	37.7	591.5	537.9	53.6
Trouble remembering	629	525	104	662.2	585	77.2	622.6	554.4	68.2
Nausea/vomiting	604.1	601.8	2.3	442.8	453.6	-10.8	420.9	410.6	10.3
Diarrhea/loose bowels	653.7	620.5	33.2	577.5	587.7	-10.2	472.4	449.1	23.3
Sad/down/depressed	808.3	589.3	219	792.3	644.8	147.5	727.5	612.9	114.6
Nervous/anxious	797.8	595.3	202.5	752.5	653.3	99.2	728.3	611.9	116.4
Difficulty sleeping	813.9	689.1	124.8	792.8	726.2	66.6	757.7	717.9	39.8
Skin problems/rash/itching	694.6	626.8	67.8	644.4	626.1	18.3	627.7	612.1	15.6
Coughing/trouble breathing	508.7	468.1	40.6	514.2	494.5	19.7	476.5	436.5	40
Headaches	662.8	645.6	17.2	625	591.3	33.7	558.1	547.6	10.5
Loss of appetite	536.1	437.6	98.5	510.3	461.1	49.2	424.5	371.9	52.6
Bloating/pain/gas in stomach	700.7	648.8	51.9	647	637.7	9.3	628	612.1	15.9
Muscle aches/joint pain	636.2	553.2	83	674.4	616.8	57.6	652.5	573.9	78.6
Problems with sex	595.4	554.8	40.6	574.3	556.6	17.7	570.8	535.7	35.1
Changes in body composition	504	473.6	30.4	557.6	554.6	3	620.6	584.3	36.3
Weight loss/wasting	402.6	377.4	25.2	389	393.9	-4.9	434.2	408.1	26.1
Hair loss/changes	358.9	335.1	23.8	344.3	343.4	0.9	313.1	309.3	3.8

Bayesian information criterion (BIC) is a criterion for model selection and the model with the lowest BIC is preferred.

**Electronic Supplementary Materials Table 1b: Unadjusted and Adjusted Associations between Treatment and Bothersome Symptoms at Weeks 4, 12 and 48 in Study GS-US-380-1844 (HIV-1 Suppressed)**

Symptom Description OR (95% CI), p-value	Week 4		Week 12		Week 48	
	Unadjusted	Adjusted	Unadjusted	Adjusted	Unadjusted	Adjusted
<b>Fatigue/loss of energy</b>	0.80 (0.56-1.14), 0.21	0.65 (0.43-0.99), 0.045 <sup>a,g</sup>	0.97 (0.69-1.37), 0.86	0.86 (0.58-1.28), 0.47 <sup>a,c,g</sup>	0.85 (0.60-1.21), 0.37	0.71 (0.47-1.07), 0.099 <sup>a,g</sup>
Fevers/chills/sweats	1.50 (0.88-2.58), 0.14	1.41 (0.76-2.59), 0.27 <sup>a,g</sup>	1.02 (0.64-1.64), 0.93	0.91 (0.55-1.50), 0.71 <sup>a</sup>	0.89 (0.52-1.53), 0.67	0.71 (0.39-1.27), 0.25 <sup>a</sup>
<b>Dizzy/lightheadedness</b>	0.69 (0.41-1.15), 0.15	0.52 (0.29-0.95), 0.033 <sup>a,g</sup>	0.87 (0.55-1.38), 0.54	0.69 (0.41-1.17), 0.17 <sup>a,e</sup>	0.82 (0.49-1.35), 0.43	0.59 (0.32-1.09), 0.091 <sup>a,c</sup>
<b>Pain/numbness/tingling in hands/feet</b>	0.85 (0.56-1.29), 0.44	0.63 (0.38-1.05), 0.077 <sup>a,f</sup>	0.84 (0.56-1.26), 0.41	0.70 (0.44-1.12), 0.13 <sup>a,f</sup>	0.80 (0.54-1.19), 0.27	0.60 (0.37-0.96), 0.033 <sup>a,c,f,h</sup>
Trouble remembering	1.36 (0.89-2.08), 0.16	1.22 (0.73-2.05), 0.44 <sup>a,e</sup>	0.86 (0.58-1.27), 0.46	0.69 (0.43-1.10), 0.12 <sup>a,e</sup>	1.06 (0.71-1.59), 0.76	0.93 (0.59-1.46), 0.74 <sup>a,e</sup>
<b>Nausea/vomiting</b>	0.85 (0.44-1.63), 0.62	0.62 (0.29-1.29), 0.20 <sup>a,f</sup>	0.48 (0.23-1.00), 0.051	0.41 (0.18-0.93), 0.032 <sup>a</sup>	0.50 (0.24-1.03), 0.058	0.32 (0.14-0.74), 0.008 <sup>a</sup>
Diarrhea/loose bowels	0.87 (0.56-1.38), 0.56	0.78 (0.47-1.27), 0.31 <sup>a,c</sup>	0.97 (0.61-1.52), 0.88	0.96 (0.59-1.56), 0.87 <sup>e</sup>	0.82 (0.49-1.37), 0.45	0.70 (0.40-1.22), 0.21 <sup>a,g,h</sup>
<b>Sad/down/depressed</b>	0.82 (0.54-1.23), 0.33	0.57 (0.34-0.96), 0.034 <sup>a,e,g</sup>	0.84 (0.57-1.24), 0.37	0.62 (0.38-1.01), 0.056 <sup>a,e,g</sup>	0.67 (0.45-0.98), 0.040	0.43 (0.27-0.70), <0.001 <sup>a,e,g,h</sup>
<b>Nervous/anxious</b>	0.83 (0.55-1.27), 0.39	0.55 (0.32-0.96), 0.035 <sup>a,e,g</sup>	0.75 (0.50-1.12), 0.17	0.58 (0.36-0.94), 0.027 <sup>a,e,g</sup>	0.76 (0.52-1.13), 0.17	0.58 (0.36-0.92), 0.021 <sup>e,g,h</sup>
<b>Difficulty sleeping</b>	0.95 (0.67-1.35), 0.77	0.80 (0.53-1.18), 0.26 <sup>a,g</sup>	0.72 (0.51-1.02), 0.066	0.56 (0.37-0.84), 0.005 <sup>a,e,g</sup>	0.86 (0.60-1.23), 0.41	0.71 (0.47-1.06), 0.096 <sup>a,e,g,h</sup>
Skin problems/rash/itching	1.00 (0.63-1.60), 1.00	0.81 (0.48-1.37), 0.43 <sup>a</sup>	0.84 (0.55-1.29), 0.44	0.72 (0.46-1.14), 0.16 <sup>a</sup>	1.06 (0.70-1.60), 0.77	0.97 (0.62-1.51), 0.88 <sup>a</sup>
Coughing/trouble breathing	1.06 (0.65-1.74), 0.80	0.98 (0.56-1.69), 0.93 <sup>a,g</sup>	1.18 (0.71-1.94), 0.53	1.08 (0.62-1.87), 0.78 <sup>a,c,e</sup>	0.87 (0.55-1.38), 0.56	0.78 (0.47-1.30), 0.35 <sup>a,e,g</sup>
Headaches	1.02 (0.66-1.58), 0.91	0.94 (0.57-1.54), 0.79 <sup>a,b,c</sup>	0.93 (0.60-1.44), 0.75	0.81 (0.50-1.32), 0.39 <sup>a,f</sup>	1.11 (0.71-1.73), 0.66	0.96 (0.58-1.59), 0.87 <sup>a,c,f</sup>
<b>Loss of appetite</b>	0.78 (0.42-1.45), 0.43	0.59 (0.28-1.25), 0.17 <sup>a</sup>	0.47 (0.24-0.89), 0.020	0.26 (0.12-0.59), 0.001 <sup>a</sup>	0.76 (0.39-1.46), 0.41	0.59 (0.27-1.29), 0.18 <sup>a,e</sup>
<b>Bloating/pain/gas in stomach</b>	0.81 (0.55-1.21), 0.31	0.70 (0.44-1.10), 0.12 <sup>a,h</sup>	0.74 (0.49-1.13), 0.17	0.62 (0.39-1.00), 0.049 <sup>a</sup>	1.00 (0.65-1.53), 0.98	0.89 (0.54-1.45), 0.64 <sup>a,h</sup>
Muscle aches/joint pain	1.00 (0.67-1.48), 1.00	0.84 (0.50-1.40), 0.50 <sup>a,f,g</sup>	1.07 (0.74-1.55), 0.71	0.99 (0.65-1.51), 0.95 <sup>a,b,f</sup>	1.17 (0.80-1.73), 0.42	1.04 (0.67-1.64), 0.85 <sup>a,c,f</sup>
Problems with sex	1.22 (0.77-1.94), 0.40	1.14 (0.68-1.91), 0.63 <sup>a,c</sup>	0.83 (0.55-1.27), 0.39	0.75 (0.47-1.18), 0.21 <sup>a,c,g</sup>	0.93 (0.61-1.41), 0.73	0.89 (0.57-1.40), 0.62 <sup>a,c,h</sup>
Changes in body composition	1.07 (0.70-1.63), 0.76	0.89 (0.54-1.47), 0.65 <sup>a,b,g,h</sup>	1.00 (0.68-1.49), 0.98	0.88 (0.56-1.37), 0.57 <sup>a,b</sup>	1.43 (0.96-2.12), 0.077	1.31 (0.85-2.03), 0.23 <sup>a,f,g,h</sup>
Weight loss/wasting	1.27 (0.64-2.50), 0.49	1.13 (0.53-2.40), 0.76 <sup>a,g</sup>	1.27 (0.73-2.21), 0.40	1.15 (0.64-2.05), 0.64 <sup>a</sup>	1.72 (0.92-3.22), 0.092	1.44 (0.73-2.83), 0.30 <sup>a,g</sup>
<b>Hair loss/changes</b>	2.44 (1.10-5.43), 0.029	2.43 (1.03-5.71), 0.042 <sup>a,c,d</sup>	0.65 (0.31-1.38), 0.26	0.54 (0.24-1.19), 0.13 <sup>a,c,d</sup>	1.04 (0.58-1.88), 0.89	0.82 (0.43-1.56), 0.54 <sup>a,c</sup>

Adjusted logistic regression model includes treatment as the independent variable and the bothersome HIVSI item as the dependent variable, adjusted for Baseline HIVSI count, age, sex, Baseline VACS Index, serious mental illness, Baseline SF-36 PCS, Baseline SF-36 MCS, and Years since HIV diagnosis.

P-value is for treatment effect; bolding indicates significant treatment effect in one or more of the models.

The following covariates were statistically significant (p<0.05) in the model: <sup>a</sup>Baseline HIVSI count; <sup>b</sup>Age; <sup>c</sup>Sex; <sup>d</sup>Baseline VACS Index; <sup>e</sup>Serious mental illness; <sup>f</sup>Baseline SF-36 PCS; <sup>g</sup>Baseline SF-36 MCS; <sup>h</sup>Years since HIV diagnosis.

An odds ratio (OR) < 1 represents less bothersome symptom for B/F/TAF

<b>Electronic Supplementary Materials Table 1b-2: Bayesian information criterion (BIC) for Unadjusted and Adjusted Associations between Treatment and Bothersome Symptoms at Weeks 4, 12 and 48 in Study GS-US-380-1844 (HIV-1 Suppressed)</b>									
<b>Symptom Description, BIC</b>	<b>Week 4</b>			<b>Week 12</b>			<b>Week 48</b>		
	<b>Unadjusted</b>	<b>Adjusted</b>	<b>Diff</b>	<b>Unadjusted</b>	<b>Adjusted</b>	<b>Diff</b>	<b>Unadjusted</b>	<b>Adjusted</b>	<b>Diff</b>
Fatigue/loss of energy	723	611	112	737.2	654.4	82.8	709.8	623.9	85.9
Fevers/chills/sweats	396	363.5	32.5	473.6	471.7	1.9	382.8	383.9	-1.1
Dizzy/lightheadedness	420.8	380.4	40.4	487.5	447.1	40.4	425.9	362.4	63.5
Pain/numbness/tingling in hands/feet	558.8	471.7	87.1	590	518.5	71.5	595.6	520.1	75.5
Trouble remembering	551.2	451.1	100.1	618.1	520.8	97.3	597.2	542.3	54.9
Nausea/vomiting	295.4	280	15.4	258.9	263.7	-4.8	266.9	255.1	11.8
Diarrhea/loose bowels	502.8	487	15.8	501	499.1	1.9	418.4	411.5	6.9
Sad/down/depressed	591	461	130	627.1	497	130.1	626.4	514.1	112.3
Nervous/anxious	561.1	420.9	140.2	601.8	500.6	101.2	619.2	524.4	94.8
Difficulty sleeping	726.7	662.4	64.3	726.7	646	80.7	691.4	627.2	64.2
Skin problems/rash/itching	479.1	445.3	33.8	549.6	540.4	9.2	572.5	550.9	21.6
Coughing/trouble breathing	449.3	412.9	36.4	436.5	414.9	21.6	491.2	457.7	33.5
Headaches	534.3	471.5	62.8	533	490.4	42.6	501.2	459.8	41.4
Loss of appetite	315	268.6	46.4	318.9	267.6	51.3	290.1	253.1	37
Bloating/pain/gas in stomach	607.7	543.8	63.9	561	518.1	42.9	530.4	480.6	49.8
Muscle aches/joint pain	613.7	455.4	158.3	682.1	596.3	85.8	624.1	540.6	83.5
Problems with sex	487.8	446.9	40.9	558.5	533.7	24.8	556	537	19
Changes in body composition	558.4	463.2	95.2	607.2	555.4	51.8	608.2	563.2	45
Weight loss/wasting	279.1	268.7	10.4	374.7	392.9	-18.2	317.5	314.1	3.4
Hair loss/changes	241.2	246.9	-5.7	244.7	262.3	-17.6	339	336.7	2.3

Bayesian information criterion (BIC) is a criterion for model selection and the model with the lowest BIC is preferred.

**Electronic Supplementary Materials Table 2a: Longitudinal Models for HIVSI Bothersome Symptoms in Study GS-US-380-1489 (Treatment-Naïve)**

	Fatigue/loss of energy	Fevers/chills/sweats	Dizzy/lightheadedness	Pain/numbness/tingling in hands/feet	Trouble remembering
Treatment (B/F/TAF vs. ABC/DTG/3TC)	-0.648 (-1.100,-0.196); 0.005	-0.123 (-0.963,0.716); 0.77	-0.797 (-1.633,0.038); 0.061	-0.592 (-1.495,0.312); 0.20	0.025 (-0.845,0.894); 0.96
Time	-0.004 (-0.014,0.005); 0.39	-0.070 (-0.102,-0.037); <0.001	-0.051 (-0.100,-0.001); 0.045	-0.049 (-0.081,-0.016); 0.003	-0.050 (-0.080,-0.020); <0.001
Time x Treatment	-0.001 (-0.014,0.013); 0.89	-0.003 (-0.038,0.032); 0.88	-0.021 (-0.054,0.013); 0.23	0.007 (-0.022,0.036); 0.65	-0.006 (-0.033,0.021); 0.64
Baseline HIVSI Bothersome Symptom Count	0.129 (0.063,0.195); <0.001	0.182 (0.054,0.311); 0.006	0.103 (-0.023,0.230); 0.11	0.147 (0.020,0.275); 0.024	0.252 (0.108,0.396); <0.001
Baseline HIVSI Bothersome Symptom (Yes vs. No)	0.834 (0.409,1.258); <0.001	2.739 (1.769,3.708); <0.001	3.022 (1.394,4.651); <0.001	4.290 (2.582,5.997); <0.001	3.537 (1.584,5.490); <0.001
Age	0.012 (-0.006,0.030); 0.18	0.004 (-0.032,0.039); 0.83	0.000 (-0.032,0.032); 1.00	0.020 (-0.014,0.055); 0.25	-0.013 (-0.051,0.025); 0.51
Sex (Female vs. Male)	0.194 (-0.378,0.765); 0.51	0.827 (-0.385,2.039); 0.18	-0.194 (-1.260,0.872); 0.72	-0.012 (-1.347,1.324); 0.99	-0.254 (-1.632,1.125); 0.72
Baseline VACS Index	-0.014 (-0.029,0.000); 0.052	-0.028 (-0.068,0.011); 0.16	-0.001 (-0.035,0.032); 0.93	0.001 (-0.032,0.034); 0.97	0.033 (0.000,0.066); 0.052
Serious mental illness (Yes vs. No)	0.373 (-0.017,0.763); 0.061	0.095 (-0.700,0.890); 0.81	-0.123 (-0.897,0.651); 0.76	0.007 (-0.831,0.846); 0.99	0.781 (-0.074,1.636); 0.073
Baseline SF-36 PCS	-0.073 (-0.105,-0.041); <0.001	-0.083 (-0.159,-0.007); 0.032	-0.089 (-0.156,-0.021); 0.010	-0.107 (-0.176,-0.038); 0.002	-0.068 (-0.144,0.009); 0.083
Baseline SF-36 MCS	-0.038 (-0.056,-0.019); <0.001	-0.026 (-0.063,0.011); 0.17	-0.055 (-0.095,-0.015); 0.007	-0.016 (-0.058,0.026); 0.46	-0.045 (-0.087,-0.003); 0.037
Unadjusted/adjusted BIC	2249.38/2010.69	1504.52/1337.49	1609.45/1422.98	1518.66/1314.63	1664.22/1434.56

(cont.)

	Nausea/vomiting*	Diarrhea/loose bowels	Sad/down/depressed	Nervous/anxious	Difficulty sleeping
Treatment (B/F/TAF vs. ABC/DTG/3TC)	-1.520 (-2.344,-0.695); <0.001	-0.203 (-0.782,0.375); 0.49	-0.530 (-1.431,0.372); 0.25	-0.408 (-0.897,0.081); 0.10	-0.368 (-0.827,0.091); 0.12
Time	-0.117 (-0.168,-0.067); <0.001	-0.080 (-0.100,-0.060); <0.001	-0.039 (-0.063,-0.015); 0.001	-0.006 (-0.019,0.008); 0.41	-0.002 (-0.017,0.012); 0.75
Time x Treatment	0.026 (-0.027,0.078); 0.34	-0.012 (-0.038,0.014); 0.37	-0.010 (-0.043,0.023); 0.54	0.000 (-0.016,0.015); 0.95	-0.007 (-0.023,0.009); 0.41
Baseline HIVSI Bothersome Symptom Count	0.022 (-0.082,0.126); 0.68	0.029 (-0.051,0.109); 0.48	0.221 (0.075,0.367); 0.003	0.181 (0.108,0.255); <0.001	0.129 (0.052,0.206); 0.001
Baseline HIVSI Bothersome Symptom (Yes vs. No)	1.929 (-0.376,4.234); 0.10	2.638 (1.580,3.697); <0.001	2.627 (0.991,4.263); 0.002	1.465 (0.904,2.026); <0.001	1.518 (0.950,2.085); <0.001
Age	-0.053 (-0.084,-0.021); 0.001	-0.017 (-0.040,0.006); 0.14	-0.011 (-0.050,0.027); 0.56	-0.001 (-0.022,0.020); 0.93	0.005 (-0.014,0.025); 0.59
Sex (Female vs. Male)	0.363 (-0.935,1.661); 0.58	-0.488 (-1.287,0.311); 0.23	0.172 (-1.052,1.396); 0.78	0.153 (-0.539,0.846); 0.66	0.371 (-0.226,0.968); 0.22
Baseline VACS Index	-0.006 (-0.036,0.023); 0.67	0.006 (-0.013,0.025); 0.52	-0.015 (-0.047,0.017); 0.36	-0.015 (-0.033,0.003); 0.094	-0.009 (-0.025,0.006); 0.23
Serious mental illness (Yes vs. No)	0.267 (-0.499,1.033); 0.49	0.321 (-0.240,0.882); 0.26	1.566 (0.554,2.579); 0.002	0.886 (0.433,1.340); <0.001	0.469 (0.040,0.898); 0.032
Baseline SF-36 PCS	-0.049 (-0.106,0.009); 0.096	-0.049 (-0.095,-0.003); 0.037	-0.078 (-0.138,-0.018); 0.010	-0.021 (-0.055,0.014); 0.24	-0.045 (-0.083,-0.007); 0.020
Baseline SF-36 MCS	-0.042 (-0.075,-0.008); 0.015	-0.024 (-0.050,0.001); 0.056	-0.143 (-0.210,-0.076); <0.001	-0.044 (-0.066,-0.023); <0.001	-0.021 (-0.042,0.000); 0.051
Unadjusted/adjusted BIC	1348.05/1278.04	1570.26/1433.84	2035.33/1646.64	1999.31/1675.05	2144.98/1934.77

(cont.)

	Skin problems/rash/itching	Coughing/trouble breathing	Headaches	Loss of appetite	Bloating/pain/gas in stomach
Treatment (B/F/TAF vs. ABC/DTG/3TC)	-0.705 (-1.541,0.132); 0.099	0.149 (-0.716,1.013); 0.74	0.081 (-0.506,0.667); 0.79	-1.320 (-2.483,-0.157); 0.026	0.285 (-0.447,1.016); 0.45
Time	-0.060 (-0.087,-0.034); <0.001	-0.060 (-0.094,-0.025); <0.001	-0.079 (-0.103,-0.055); <0.001	-0.073 (-0.117,-0.030); 0.001	-0.059 (-0.083,-0.035); <0.001
Time x Treatment	0.009 (-0.021,0.038); 0.56	-0.004 (-0.038,0.029); 0.80	-0.036 (-0.062,-0.009); 0.010	-0.021 (-0.071,0.029); 0.42	-0.033 (-0.062,-0.005); 0.023
Baseline HIVSI Bothersome Symptom Count	0.194 (0.063,0.325); 0.004	0.128 (0.002,0.253); 0.046	0.150 (0.054,0.245); 0.002	0.214 (0.062,0.367); 0.006	0.127 (0.007,0.246); 0.037
Baseline HIVSI Bothersome Symptom (Yes vs. No)	2.550 (1.430,3.670); <0.001	3.325 (1.147,5.503); 0.003	1.797 (0.750,2.844); <0.001	2.689 (0.946,4.431); 0.003	2.981 (1.055,4.907); 0.002
Age	-0.018 (-0.054,0.017); 0.31	0.035 (-0.003,0.072); 0.068	-0.024 (-0.050,0.002); 0.074	-0.104 (-0.165,-0.044); <0.001	-0.015 (-0.048,0.019); 0.39
Sex (Female vs. Male)	0.440 (-0.810,1.690); 0.49	0.605 (-0.434,1.643); 0.25	0.803 (-0.079,1.686); 0.074	-0.016 (-1.635,1.602); 0.98	0.013 (-1.192,1.219); 0.98
Baseline VACS Index	0.018 (-0.014,0.051); 0.26	-0.020 (-0.056,0.016); 0.28	-0.011 (-0.033,0.011); 0.33	0.017 (-0.037,0.072); 0.53	0.001 (-0.027,0.029); 0.95
Serious mental illness (Yes vs. No)	0.111 (-0.629,0.850); 0.77	-0.425 (-1.346,0.496); 0.37	-0.060 (-0.649,0.529); 0.84	0.416 (-0.593,1.425); 0.42	-0.381 (-1.145,0.382); 0.33
Baseline SF-36 PCS	-0.099 (-0.169,-0.028); 0.006	-0.107 (-0.167,-0.047); <0.001	-0.041 (-0.084,0.002); 0.063	-0.213 (-0.319,-0.108); <0.001	-0.085 (-0.150,-0.019); 0.011
Baseline SF-36 MCS	-0.033 (-0.070,0.004); 0.083	-0.032 (-0.068,0.005); 0.091	0.003 (-0.022,0.028); 0.83	-0.037 (-0.083,0.010); 0.12	-0.038 (-0.071,-0.006); 0.019
Unadjusted/adjusted BIC	1780.05/1608.28	1322.62/1152.49	1711.73/1569.23	1173.84/1021.75	1803.08/1646.55

(cont.)

	Muscle aches/joint pain	Problems with sex	Changes in body composition	Weight loss/wasting	Hair loss/changes
Treatment (B/F/TAF vs. ABC/DTG/3TC)	0.077 (-0.755,0.909); 0.86	0.399 (-0.457,1.254); 0.36	0.817 (-0.027,1.661); 0.058	-0.701 (-1.607,0.205); 0.13	-0.662 (-1.805,0.480); 0.26
Time	-0.015 (-0.075,0.045); 0.63	-0.069 (-0.098,-0.040); <0.001	-0.038 (-0.062,-0.015); 0.001	-0.048 (-0.091,-0.005); 0.030	-0.059 (-0.121,0.003); 0.061
Time x Treatment	-0.011 (-0.039,0.016); 0.42	-0.015 (-0.047,0.017); 0.36	-0.027 (-0.051,-0.003); 0.030	0.008 (-0.020,0.036); 0.59	-0.010 (-0.063,0.043); 0.70
Baseline HIVSI Bothersome Symptom Count	0.134 (0.019,0.248); 0.023	0.086 (-0.029,0.200); 0.14	0.087 (-0.016,0.189); 0.097	0.128 (0.023,0.233); 0.017	0.068 (-0.058,0.194); 0.29
Baseline HIVSI Bothersome Symptom (Yes vs. No)	2.795 (1.541,4.048); <0.001	3.965 (2.923,5.006); <0.001	4.734 (2.825,6.642); <0.001	1.290 (-0.237,2.818); 0.097	4.242 (0.819,7.665); 0.015
Age	0.037 (0.001,0.074); 0.045	-0.007 (-0.045,0.030); 0.70	0.013 (-0.024,0.050); 0.50	-0.042 (-0.079,-0.006); 0.023	-0.072 (-0.128,-0.017); 0.011
Sex (Female vs. Male)	1.312 (0.020,2.605); 0.047	-0.441 (-1.661,0.779); 0.48	0.719 (-0.555,1.993); 0.27	0.370 (-0.727,1.466); 0.51	0.846 (-0.347,2.039); 0.16
Baseline VACS Index	0.003 (-0.025,0.032); 0.82	-0.003 (-0.034,0.028); 0.86	-0.010 (-0.045,0.024); 0.55	0.008 (-0.017,0.034); 0.52	0.062 (0.012,0.113); 0.016
Serious mental illness (Yes vs. No)	-0.177 (-0.990,0.636); 0.67	-0.187 (-1.061,0.687); 0.67	-0.120 (-0.896,0.657); 0.76	0.347 (-0.372,1.067); 0.34	-0.109 (-1.135,0.917); 0.83
Baseline SF-36 PCS	-0.140 (-0.225,-0.055); 0.001	-0.099 (-0.168,-0.031); 0.004	-0.074 (-0.136,-0.011); 0.021	-0.078 (-0.141,-0.015); 0.015	-0.069 (-0.140,0.002); 0.056
Baseline SF-36 MCS	-0.044 (-0.079,-0.008); 0.016	-0.055 (-0.093,-0.017); 0.004	-0.012 (-0.044,0.019); 0.45	0.000 (-0.034,0.035); 0.98	-0.013 (-0.057,0.031); 0.56
Unadjusted/adjusted BIC	1747.47/1534.11	1549.49/1317.58	1469.97/1265.36	1030.99/941.73	764.97/686.93

Models used an unstructured covariance structure, except those denoted by a \*, which used a variance component structure instead.

A negative coefficient for time suggests the prevalence declines over time, while a negative term for treatment suggests a lower prevalence associated with the switch group. Similarly, a negative interaction term for time and treatment group indicates either a more rapid decline (if the main term for time is negative) or a slower increase in the prevalence of the symptom

**Abbreviations:** ABC/DTG/3TC, Abacavir/Dolutegravir/Lamivudine; B/F/TAF, Bictegravir/Emtricitabine/Tenofovir Alafenamide; BIC, Bayesian information criterion; CI, confidence interval; HIVSI, HIV Symptom Index; SF-36 MCS, Short Form 36 Mental Composite Score; SF-36 PCS, Short Form 36 Physical Composite Score; VACS, Veterans Aging Cohort Study.

**Electronic Supplementary Materials Table 2b: Longitudinal Models for HIVSI Bothersome Symptoms in Study GS-US-380-1844 (HIV-1 Suppressed)**

	Fatigue/loss of energy*	Fevers/chills/sweats	Dizzy/lightheadedness*	Pain/numbness/tingling in hands/feet	Trouble remembering
Treatment (B/F/TAF vs. ABC/DTG/3TC)	-0.387 (-0.839,0.065); 0.093	0.294 (-0.534,1.122); 0.49	-0.745 (-1.368,-0.122); 0.019	-0.639 (-1.673,0.396); 0.23	-0.018 (-1.264,1.228); 0.98
Time	0.005 (-0.004,0.015); 0.28	-0.041 (-0.095,0.013); 0.13	-0.002 (-0.014,0.009); 0.70	-0.020 (-0.063,0.023); 0.36	-0.008 (-0.040,0.024); 0.64
Time x Treatment	-0.001 (-0.015,0.013); 0.86	-0.026 (-0.058,0.006); 0.12	0.004 (-0.015,0.024); 0.64	-0.005 (-0.035,0.025); 0.76	-0.008 (-0.040,0.024); 0.63
Baseline HIVSI Bothersome Symptom Count	0.077 (0.007,0.147); 0.032	0.102 (-0.029,0.233); 0.13	0.144 (0.066,0.223); <0.001	0.132 (-0.008,0.273); 0.065	0.224 (0.023,0.424); 0.029
Baseline HIVSI Bothersome Symptom (Yes vs. No)	1.719 (1.262,2.175); <0.001	3.556 (1.446,5.667); <0.001	1.686 (1.005,2.367); <0.001	5.462 (2.745,8.180); <0.001	9.947 (2.383,17.512); 0.010
Age	-0.016 (-0.041,0.008); 0.18	0.015 (-0.029,0.059); 0.50	-0.007 (-0.036,0.022); 0.64	-0.003 (-0.052,0.046); 0.90	0.051 (-0.007,0.109); 0.084
Sex (Female vs. Male)	-0.474 (-1.018,0.070); 0.087	0.526 (-0.569,1.621); 0.35	0.483 (-0.134,1.100); 0.12	0.198 (-1.343,1.739); 0.80	0.037 (-1.258,1.332); 0.96
Baseline VACS Index	0.007 (-0.016,0.029); 0.57	-0.037 (-0.088,0.015); 0.16	0.006 (-0.023,0.034); 0.69	0.010 (-0.034,0.054); 0.65	-0.024 (-0.078,0.031); 0.40
Serious mental illness (Yes vs. No)	0.371 (-0.015,0.757); 0.059	0.314 (-0.361,0.988); 0.36	0.439 (-0.043,0.921); 0.074	0.709 (-0.080,1.499); 0.078	1.116 (0.257,1.974); 0.011
Baseline SF-36 PCS	-0.019 (-0.046,0.008); 0.18	-0.016 (-0.073,0.040); 0.57	-0.005 (-0.038,0.027); 0.74	-0.114 (-0.187,-0.040); 0.003	-0.017 (-0.079,0.046); 0.60
Baseline SF-36 MCS	-0.071 (-0.094,-0.047); <0.001	-0.059 (-0.102,-0.016); 0.008	-0.038 (-0.064,-0.011); 0.005	-0.032 (-0.086,0.023); 0.25	-0.040 (-0.101,0.021); 0.20
Years Since HIV Diagnosis	0.014 (-0.013,0.041); 0.30	0.018 (-0.029,0.064); 0.46	0.017 (-0.016,0.050); 0.32	0.025 (-0.034,0.085); 0.41	0.000 (-0.062,0.061); 0.99
Unadjusted/adjusted BIC	1947.25/1677.59	1117.93/1013.95	1178.85/1036.16	1477.73/1229.06	1429.71/1130.70

(cont.)

	Nausea/vomiting	Diarrhea/loose bowels*	Sad/down/depressed*	Nervous/anxious*	Difficulty sleeping*
Treatment (B/F/TAF vs. ABC/DTG/3TC)	-0.846 (-1.484,-0.209); 0.009	-0.245 (-0.905,0.416); 0.47	-0.581 (-1.155,-0.008); 0.047	-0.990 (-1.966,-0.015); 0.047	-0.516 (-0.996,-0.036); 0.035
Time	0.024 (0.012,0.037); <0.001	-0.077 (-0.106,-0.049); <0.001	0.016 (0.002,0.030); 0.029	-0.022 (-0.049,0.004); 0.099	0.000 (-0.012,0.012); 0.98
Time x Treatment	-0.005 (-0.028,0.019); 0.70	-0.003 (-0.033,0.028); 0.85	-0.011 (-0.028,0.007); 0.24	-0.001 (-0.026,0.023); 0.91	0.001 (-0.014,0.015); 0.93
Baseline HIVSI Bothersome Symptom Count	0.177 (0.073,0.280); <0.001	-0.032 (-0.134,0.071); 0.55	0.072 (-0.005,0.150); 0.068	0.135 (-0.023,0.293); 0.094	0.083 (0.010,0.157); 0.027
Baseline HIVSI Bothersome Symptom (Yes vs. No)	1.678 (0.954,2.401); <0.001	3.709 (2.262,5.156); <0.001	1.595 (0.888,2.301); <0.001	3.576 (1.546,5.607); <0.001	1.713 (1.178,2.248); <0.001
Age	-0.009 (-0.039,0.022); 0.58	-0.011 (-0.048,0.026); 0.57	0.018 (-0.011,0.046); 0.23	0.001 (-0.046,0.047); 0.98	0.006 (-0.020,0.033); 0.64
Sex (Female vs. Male)	0.696 (0.028,1.364); 0.041	-1.768 (-2.873,-0.663); 0.002	0.057 (-0.647,0.762); 0.87	0.488 (-0.772,1.748); 0.45	-0.127 (-0.792,0.538); 0.71
Baseline VACS Index	-0.017 (-0.046,0.013); 0.26	-0.011 (-0.052,0.029); 0.59	-0.017 (-0.045,0.010); 0.22	-0.031 (-0.081,0.019); 0.23	-0.014 (-0.039,0.010); 0.25
Serious mental illness (Yes vs. No)	0.209 (-0.260,0.679); 0.38	0.619 (0.042,1.196); 0.036	0.999 (0.534,1.465); <0.001	1.344 (0.531,2.157); 0.001	0.883 (0.462,1.304); <0.001
Baseline SF-36 PCS	-0.001 (-0.042,0.039); 0.94	-0.058 (-0.103,-0.013); 0.012	-0.029 (-0.063,0.005); 0.095	-0.013 (-0.073,0.048); 0.68	-0.014 (-0.044,0.015); 0.33
Baseline SF-36 MCS	-0.010 (-0.046,0.025); 0.57	-0.045 (-0.082,-0.008); 0.018	-0.100 (-0.131,-0.069); <0.001	-0.130 (-0.200,-0.060); <0.001	-0.051 (-0.077,-0.025); <0.001
Years Since HIV Diagnosis	-0.029 (-0.065,0.008); 0.12	0.003 (-0.038,0.044); 0.89	0.017 (-0.014,0.049); 0.27	0.008 (-0.050,0.066); 0.79	0.021 (-0.008,0.050); 0.16
Unadjusted/adjusted BIC	722.60/710.94	1217.13/1073.23	1599.87/1312.86	1515.45/1240.54	1925.51/1696.95



(cont.)

	Skin problems/rash/itching	Coughing/trouble breathing	Headaches	Loss of appetite	Bloating/pain/gas in stomach
Treatment (B/F/TAF vs. ABC/DTG/3TC)	-0.840 (-1.784,0.104); 0.081	0.024 (-0.909,0.958); 0.96	-0.378 (-1.246,0.490); 0.39	-2.121 (-4.010,-0.231); 0.028	-0.701 (-1.438,0.036); 0.062
Time	-0.061 (-0.089,-0.034); <0.001	-0.037 (-0.088,0.015); 0.16	-0.046 (-0.089,-0.003); 0.035	-0.012 (-0.050,0.025); 0.52	-0.063 (-0.094,-0.033); <0.001
Time x Treatment	0.013 (-0.015,0.041); 0.36	-0.006 (-0.037,0.025); 0.70	0.005 (-0.026,0.037); 0.74	0.004 (-0.063,0.072); 0.91	0.015 (-0.010,0.041); 0.24
Baseline HIVSI Bothersome Symptom Count	0.263 (0.096,0.429); 0.002	0.060 (-0.068,0.189); 0.35	0.236 (0.094,0.378); 0.001	0.234 (0.025,0.443); 0.029	0.117 (-0.015,0.248); 0.082
Baseline HIVSI Bothersome Symptom (Yes vs. No)	3.976 (2.216,5.736); <0.001	3.677 (2.271,5.082); <0.001	3.311 (1.365,5.258); <0.001	7.504 (3.311,11.697); <0.001	3.520 (1.794,5.246); <0.001
Age	0.033 (-0.010,0.076); 0.13	0.015 (-0.027,0.057); 0.48	-0.033 (-0.078,0.012); 0.15	0.017 (-0.062,0.096); 0.67	-0.018 (-0.055,0.019); 0.33
Sex (Female vs. Male)	-0.177 (-1.660,1.307); 0.81	-1.427 (-2.942,0.089); 0.065	1.326 (-0.082,2.734); 0.065	0.619 (-1.143,2.381); 0.49	0.214 (-0.824,1.252); 0.69
Baseline VACS Index	-0.028 (-0.072,0.016); 0.21	-0.023 (-0.069,0.023); 0.33	-0.011 (-0.055,0.033); 0.62	-0.022 (-0.100,0.056); 0.58	0.007 (-0.029,0.043); 0.70
Serious mental illness (Yes vs. No)	0.769 (0.083,1.456); 0.028	1.039 (0.349,1.730); 0.003	0.242 (-0.491,0.975); 0.52	1.799 (0.127,3.470); 0.035	-0.102 (-0.718,0.514); 0.75
Baseline SF-36 PCS	-0.015 (-0.085,0.055); 0.67	-0.057 (-0.108,-0.007); 0.027	-0.083 (-0.141,-0.026); 0.005	-0.036 (-0.119,0.046); 0.39	-0.014 (-0.062,0.034); 0.57
Baseline SF-36 MCS	-0.002 (-0.055,0.051); 0.94	-0.083 (-0.126,-0.039); <0.001	0.003 (-0.039,0.046); 0.88	-0.008 (-0.072,0.057); 0.82	-0.065 (-0.105,-0.025); 0.002
Years Since HIV Diagnosis	-0.006 (-0.058,0.046); 0.82	0.016 (-0.033,0.066); 0.52	-0.009 (-0.060,0.042); 0.74	0.011 (-0.076,0.098); 0.80	0.054 (0.010,0.098); 0.017
Unadjusted/adjusted BIC	1464.75/1248.38	1230.49/1065.05	1391.50/1215.47	625.71/558.28	1493.28/1281.65

(cont.)

	Muscle aches/joint pain	Problems with sex	Changes in body composition	Weight loss/wasting	Hair loss/changes
Treatment (B/F/TAF vs. ABC/DTG/3TC)	-0.203 (-0.972,0.566); 0.60	0.519 (-0.426,1.464); 0.28	-0.753 (-1.892,0.385); 0.19	-0.215 (-1.215,0.786); 0.67	0.441 (-0.659,1.541); 0.43
Time	-0.025 (-0.148,0.097); 0.68	-0.033 (-0.074,0.009); 0.12	-0.044 (-0.083,-0.004); 0.030	-0.074 (-0.116,-0.033); <0.001	-0.001 (-0.038,0.035); 0.94
Time x Treatment	0.010 (-0.017,0.037); 0.46	-0.012 (-0.038,0.013); 0.34	0.030 (0.000,0.060); 0.054	0.018 (-0.020,0.056); 0.36	-0.026 (-0.060,0.007); 0.13
Baseline HIVSI Bothersome Symptom Count	0.169 (-0.043,0.381); 0.12	-0.023 (-0.160,0.113); 0.74	0.120 (-0.050,0.289); 0.17	0.086 (-0.042,0.214); 0.19	0.105 (-0.014,0.224); 0.083
Baseline HIVSI Bothersome Symptom (Yes vs. No)	2.086 (-0.606,4.778); 0.13	6.115 (3.173,9.057); <0.001	6.822 (2.967,10.676); <0.001	4.059 (2.260,5.858); <0.001	3.074 (1.644,4.505); <0.001
Age	0.036 (-0.012,0.084); 0.14	0.036 (-0.017,0.089); 0.18	0.059 (-0.001,0.118); 0.054	-0.010 (-0.063,0.043); 0.72	0.019 (-0.032,0.069); 0.47
Sex (Female vs. Male)	0.873 (-0.264,2.011); 0.13	-1.214 (-2.661,0.234); 0.10	0.468 (-1.147,2.084); 0.57	0.046 (-1.333,1.424); 0.95	1.659 (0.277,3.041); 0.019
Baseline VACS Index	-0.017 (-0.054,0.020); 0.36	-0.027 (-0.078,0.023); 0.29	-0.014 (-0.078,0.050); 0.66	0.010 (-0.039,0.059); 0.70	-0.026 (-0.083,0.031); 0.37
Serious mental illness (Yes vs. No)	0.178 (-0.458,0.813); 0.58	0.885 (0.150,1.620); 0.018	0.091 (-0.791,0.973); 0.84	0.167 (-0.648,0.982); 0.69	0.367 (-0.380,1.114); 0.33
Baseline SF-36 PCS	-0.105 (-0.256,0.046); 0.17	-0.052 (-0.117,0.013); 0.12	-0.038 (-0.106,0.030); 0.27	0.008 (-0.059,0.074); 0.82	-0.005 (-0.071,0.062); 0.89
Baseline SF-36 MCS	-0.046 (-0.113,0.021); 0.18	-0.063 (-0.114,-0.011); 0.017	-0.084 (-0.142,-0.027); 0.004	-0.068 (-0.116,-0.020); 0.006	-0.001 (-0.047,0.045); 0.96
Years Since HIV Diagnosis	0.028 (-0.028,0.084); 0.32	0.037 (-0.020,0.093); 0.20	0.052 (-0.009,0.114); 0.096	0.012 (-0.042,0.067); 0.66	-0.020 (-0.083,0.042); 0.52
Unadjusted/adjusted BIC	1673.95/1413.57	1322.61/1120.83	1496.88/1163.67	795.33/740.56	661.30/552.87

Models used an unstructured covariance structure, except those denoted by a \*, which used a variance component structure instead.

A negative coefficient for time suggests the prevalence declines over time, while a negative term for treatment suggests a lower prevalence associated with the B/F/TAF group.

**Abbreviations:** ABC/DTG/3TC, Abacavir/Dolutegravir/Lamivudine; B/F/TAF, Bictegravir/Emtricitabine/Tenofovir Alafenamide; BIC, Bayesian information criterion; CI, confidence interval; HIVSI, HIV Symptom Index; SF-36 MCS, Short Form 36 Mental Composite Score; SF-36 PCS, Short Form 36 Physical Composite Score; VACS, Veterans Aging Cohort Study.